DK1416965T3 - Assayfremgangsmåde til Alzheimers sygdom - Google Patents

Assayfremgangsmåde til Alzheimers sygdom

Info

Publication number
DK1416965T3
DK1416965T3 DK02766022T DK02766022T DK1416965T3 DK 1416965 T3 DK1416965 T3 DK 1416965T3 DK 02766022 T DK02766022 T DK 02766022T DK 02766022 T DK02766022 T DK 02766022T DK 1416965 T3 DK1416965 T3 DK 1416965T3
Authority
DK
Denmark
Prior art keywords
disease
alzheimer
beta
assay procedure
preclinical
Prior art date
Application number
DK02766022T
Other languages
English (en)
Inventor
David M Holtzman
Ronald Demattos
David J Cummins
Kelly R Bales
Steven M Paul
Original Assignee
Univ Washington
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Lilly Co Eli filed Critical Univ Washington
Application granted granted Critical
Publication of DK1416965T3 publication Critical patent/DK1416965T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK02766022T 2001-08-17 2002-08-16 Assayfremgangsmåde til Alzheimers sygdom DK1416965T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31322101P 2001-08-17 2001-08-17
US31322401P 2001-08-17 2001-08-17
US33498701P 2001-10-23 2001-10-23
PCT/US2002/026321 WO2003015617A2 (en) 2001-08-17 2002-08-16 Assay method for alzheimer's disease

Publications (1)

Publication Number Publication Date
DK1416965T3 true DK1416965T3 (da) 2008-05-05

Family

ID=27405654

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02766022T DK1416965T3 (da) 2001-08-17 2002-08-16 Assayfremgangsmåde til Alzheimers sygdom

Country Status (11)

Country Link
EP (1) EP1416965B8 (da)
JP (2) JP4511830B2 (da)
AT (1) ATE381346T1 (da)
CA (1) CA2457145C (da)
CY (1) CY1107901T1 (da)
DE (1) DE60224200T2 (da)
DK (1) DK1416965T3 (da)
ES (1) ES2295401T3 (da)
HK (1) HK1061960A1 (da)
PT (1) PT1416965E (da)
WO (1) WO2003015617A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2008595A3 (cs) 2000-02-24 2017-05-03 Washington University Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci
PT1944040E (pt) 2001-08-17 2012-10-31 Univ Washington Método de avaliação para a doença de alzheimer
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7575747B2 (en) 2003-02-10 2009-08-18 Applied Molecular Evolution Aβ binding molecules
EP1480041A1 (en) * 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
CN101432302A (zh) 2005-11-30 2009-05-13 艾博特公司 抗－Aβ球聚体抗体，其抗原结合部分，相应的杂交瘤、核酸、载体、宿主细胞，生产所述抗体的方法，包含所述抗体的组合物，所述抗体的应用以及使用所述抗体的方法
CA2631195C (en) 2005-11-30 2016-04-05 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN101981053B (zh) 2007-01-18 2013-11-13 伊莱利利公司 聚乙二醇化的AβFAB
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
WO2010093001A1 (ja) * 2009-02-13 2010-08-19 国立大学法人大阪大学 アルツハイマー病の診断方法および診断薬
KR101531949B1 (ko) 2009-12-11 2015-06-26 아라클론 바이오테크, 에스.엘. 아밀로이드 베타 펩티드의 개선된 검출 방법 및 시약
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
US20170336395A1 (en) * 2013-11-20 2017-11-23 University Of Iowa Research Foundation Methods and compositions for treating amyloid deposits
CN109187981A (zh) * 2018-08-01 2019-01-11 万东山 一种快速检测β-淀粉样蛋白的量子点免疫层析试纸条与应用
WO2020031116A1 (en) * 2018-08-08 2020-02-13 Seoul National University R&Db Foundation Method of diagnosing and treating alzheimer disease using plasma tau level in conjunt ion with beta-amyloid level as diagnostic index

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333144T2 (de) * 1992-10-26 2004-05-19 Elan Pharmaceuticals, Inc., San Francisco Verfahren zur Identifizierung von Hemmstoffe der Produktion des beta-Amyloidpeptids
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6730778B2 (en) * 1997-12-19 2004-05-04 Pharmacia And Upjohn Company Human sel-10 polypeptides and polynucleotides that encode them
CZ2008595A3 (cs) * 2000-02-24 2017-05-03 Washington University Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci

Also Published As

Publication number Publication date
EP1416965A2 (en) 2004-05-12
ATE381346T1 (de) 2008-01-15
CY1107901T1 (el) 2013-09-04
CA2457145A1 (en) 2003-02-27
JP5162553B2 (ja) 2013-03-13
CA2457145C (en) 2010-12-21
EP1416965B8 (en) 2008-02-13
HK1061960A1 (en) 2004-10-15
PT1416965E (pt) 2008-04-01
ES2295401T3 (es) 2008-04-16
WO2003015617A3 (en) 2004-01-29
JP2010044078A (ja) 2010-02-25
DE60224200T2 (de) 2008-07-10
EP1416965B1 (en) 2007-12-19
WO2003015617A2 (en) 2003-02-27
JP2004538477A (ja) 2004-12-24
EP1416965A4 (en) 2005-11-02
JP4511830B2 (ja) 2010-07-28
DE60224200D1 (de) 2008-01-31

Similar Documents

Publication Publication Date Title
CY1107901T1 (el) Μεθοδος προσδιορισμου για ασθενεια alzheimer
EP1944040A3 (en) Assay method for Alzheimer's disease
DE60235746D1 (de) Antikörper gegen Alzheimer spezifische tau Proteine mit abnormaler Konformation
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
EP1778880A4 (en) METHOD AND REAGENT FOR DIAGNOSIS OF HANTAVIRUS INFECTIONS
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
WO2000018954A3 (en) Use of pex in the treatment of metabolic bone diseases
ES2138729T3 (es) Metodos de diagnostico de la preeclampsia.
DE69626683D1 (de) Verfahren zur feststellung von antipolymerantikörper und diagnosetestsatz zur feststellung von siliconabhängigen krankheiten
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
ATE318328T1 (de) Diagnostika und therapeutika für osteoporose
ATE159300T1 (de) Monoklonale antikörper gegen menschliches ige
EP1017845A4 (en) ANALYSIS FOR DIAGNOSING ALZHEIMER'S DISEASE
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
BRPI0407213A (pt) Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados
WO2002016636A3 (en) Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
WO2004038411A3 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
AU2002366555A1 (en) Diagnostic for early stage alzheimer's disease
ATE473295T1 (de) Nukleotidträger zur diagnose und therapie oraler erkrankungen
WO2002088345A3 (en) Murine dnasex, medicament containing the same and non-human mammal comprising modified dnasex gene
FR2837284B1 (fr) Methode de diagnostic serologique in vitro des endocardites infectieuses
DE69915437D1 (de) Plasmasammlungen von mehr als 200 gesunden Patienten und davon abgeleiteter Kalibrierstandard
WO2003104811A3 (en) DIAGNOSTIC AND THERAPEUTIC USE OF THE ACUTE STEROIDOGEN RESPONSE REGULATORY PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES